Document NeN3LX4GqKgJ46v7bOMY4wm1b

TO: Distribution n FROM: DATE: Interoffice STJBJ: Communication X. G. Grumbles March 19, 1987 VISTA TOXICOLOGY ASSESSMENT COMMITTEE MEETING CONFERENCE CALL OF MARCH 12 A conference call meeting of the VTAC was held on March 12. Those participating were Carl Kerfoot, Allen Nielsen, Bill McClain and myself. An agenda of items discussed is attached and all additional items also considered are so noted below. Following is a summary of the items discussed and action items. 1. It was agreed by the committee that testing is needed for any 1620 ethoxylate ultimately produced for a customer. Currently the business area is unsure if the final product commercialized will be a 4- or 8-mole ethoxylate. Since there is the potential for a significantly different toxicity profile to exist between a 4-mole and an 8-raole ethoxylate of the same alcohol testing would need to be done on both unless an indication is given by the business area regarding the most likely end product. Regardless, the testing to be recommended will include skin and eye irritation and dermal toxicity. Action Item: TGG will write recommendation letter to Charlie Matson. The letter will include the rationale, for the NCED to test both products. 2. Recent R & D activity regarding the development of C]_q Alfonic ether sulfates was reviewed. Currently this is a high priority at a customer, but the exact formulation desired is not known at this time. The end product will be used in shampoo formulations. Currently samples of 10-22 ES and 10-46 ES are being blended to achieve the final-product specifications desired. The actual end product is unclear at this time. Regardless of the final product, testing will be needed. The testing recommendation would include skin and eye irritancy and dermal toxicity. Action Item: TGG will review the available literature to determine if data for similar products exists. Action Item: Based on the results of the literature search, the business area will be advised by TGG of the testing needed if a product is commercialized. i. Action Item: OKC will closely monitor the product development. VVV 000009091 Distribution March 19, 1987 Page 2 3. The DAB product to be developed at Baltimore was reviewed. This is a new product for Vista and unique to the industry. Subsequently, no data is known to exist and testing will be needed. Based on the potential for the presence for multi-ring aromatics, this product should be screened for PNA's of concern. A protocol was developed several years ago in R & D for this and should be "resurrected" for use. The testing recommended will include the PNA analytical screening, skin and eye irritancy, and dermal toxicity. Further testing needs will be reviewed based on the results of the PNA screening. Action Item: OKC will revive and review the PNA GC/MASS SPEC screening method in Ponca City. Action Item: needs. TGG will advise the business area of the testing Additional items below were not on the agenda, but were reviewed. 4. The need for further testing for alfonic 1618-65 was discussed. The history of the product testing was reviewed. Letters summarizing the history are attached. Briefly, 1618-65 exhibits an unusual and unexpected dermal toxicity when compared to similar ethoxylates. The basis of our discussion was what further testing might be done to explain or solve the discrepancy. The business area supports further testing to assist in product development. Action Item: TGG will consult with a toxicologist to review the data and determine the next step. This will be communicated to the business and marketing area. 5. The current development work for a LPA/Paraffin alkylate-type product was discussed. Little is known regarding product potential, but the development will be closely followed. Based on currently available data testing similar to product testing would be recommended. DAB, 6. There is a growing need and an increasing number of requests for aquatic toxicity data. This was discussed in general and further consideration will be given in the future for those needs. VVV 000009092 Distribution March 19, 1987 Page 3 Action Item: AN will compile a summary of internal (published and unpublished) data similar to the summary we have for mamallion data. 7. The need to more closely monitor the dioxane levels in our ether sulfates was reviewed. At present, these products are predominately tolled at present. Charlie Matson has been asked to contact our toll processors with specific data needs. Action Item: TGG will contact Charlie regarding the request. Having no other current business, the meeting was ended. T. G. Grumbles djm Distribution: Carl Kerfoot Allen Nielsen Bill McClain cc: Dave Kuhn Charlie Starks VVV 000009093